Several major health insurers say they will continue paying for Genentech's Avastin for the treatment of breast cancer, based on a recommendation from the National Comprehensive Cancer Network, Bloomberg Businessweek reports (Larkin, Bloomberg Businessweek, 1/10)...
More...